CJC 1295 & Ipamorelin Blend (No DAC) X 10mg
Regular price
Rs. 11,953
- Unit price
- per
100% Authentic
Made in USA
Authorised distributor
1-5 Days delivery
CJC 1295 & Ipamorelin Blend (No DAC) X 10mg
Regular price
Rs. 11,953
- Unit price
- per
Price includes all duties and taxes
SKU: CJIP55
FMI's Choice
CJC-1295 & Ipamorelin Blend - Growth Hormone Secretagogue Research Complex (10 mg, No DAC)
This peptide blend combines CJC-1295 (No DAC) and Ipamorelin, two complementary growth hormone secretagogues that act on distinct receptor pathways to amplify GH release.
Mechanistic Claims
- CJC-1295 (No DAC, 5 mg)
- Synthetic GHRH analog retaining 29 amino acids of native GHRH with four substitutions for stability and receptor affinity.
- Stimulates pituitary GHRH receptors to increase pulsatile GH secretion.
- Elevates circulating IGF-1 levels, supporting anabolic and regenerative pathways.
- Mimics natural GH release patterns without prolonged receptor binding.
- Ipamorelin (5 mg)
-
- Synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).
- Selective ghrelin receptor agonist that triggers GH release from the pituitary.
- High potency with minimal off-target hormonal effects (does not significantly affect cortisol, prolactin, or ACTH).
- Provides a clean GH stimulation profile compared to other GHS compounds.
Synergistic Potential
- Dual receptor targeting (GHRH + ghrelin) amplifies GH release.
- Promotes IGF-1 elevation while maintaining physiological GH pulsatility.
- Offers a balanced approach to studying growth hormone dynamics without excessive endocrine disruption.
Research Applications
- Growth hormone secretion and regulation studies
- IGF-1 mediated anabolic and regenerative pathways
- Comparative analysis of GHRH vs. ghrelin receptor agonism
- Endocrine signaling and pituitary function models
CJC 1295 Ipamorelin Research
CJC-1295 and ipamorelin have both been researched for their potential to stimulate growth hormone production.
Ipamorelin is a potent and selective GH secretagogue with unique properties that differentiate it from other GH-releasing peptides. Its ability to selectively stimulate GH release without affecting other hormones, along with its potential applications in body composition, make it a promising candidate for further clinical development.
Growth Hormone Release
In GHRH knockout mice, CJC-1295 administration normalized body weight and length, demonstrating its potential in treating growth deficiencies. Daily administration was more effective than less frequent dosing.1
In healthy subjects, CJC-1295 led to dose-dependent increases in GH and IGF-I levels, with effects lasting up to 28 days. In the study, CJC-1295 was well-tolerated with no serious adverse reactions reported, suggesting its potential utility as a therapeutic agent.2
Ipamorelin mimics the action of ghrelin by binding to the ghrelin receptor (GHSR) in the brain, which leads to the selective stimulation of GH release from the pituitary gland. This mechanism is similar to that of GHRH, but ipamorelin does not significantly affect the release of other hormones such as ACTH or cortisol.3
In animal studies, ipamorelin has been shown to increase longitudinal bone growth and body weight gain in a dose-dependent manner. It enhances GH release without affecting other growth factors like IGF-I, suggesting a direct effect on growth processes.4
In vivo, ipamorelin shows dose-proportional pharmacokinetics with a short half-life and effectively stimulated GH release across various doses.5
References
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291 6, E1290-4 . https://doi.org/10.1152/AJPENDO.00201.2006.
- Teichman, S., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 91 3, 799-805 . https://doi.org/10.1210/JC.2005-1536.
- Raun, K., Hansen, B., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology, 139 5, 552-61 . https://doi.org/10.1530/EJE.0.1390552.
- Johansen, P., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 9 2, 106-13 . https://doi.org/10.1054/GHIR.1999.9998.
- Gobburu, J., Agersø, H., Jusko, W., & Ynddal, L. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research, 16, 1412-1416. https://doi.org/10.1023/A:1018955126402.
Label-- Peptide Information
|
Property |
Value |
|---|---|
|
Peptide Name |
CJC 1295 |
|
Peptide Sequence |
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys |
|
Molecular Formula |
C165H269N47O46 |
|
Molecular Weight |
3647.2 g/mol |
|
CAS Number |
446262-90-4 |
|
PubChem CID |
91971820 |
|
Synonyms |
CJC 1295, CJC-1295, 62RC32V9N7, DTXSID501027567 |
| Property | Value |
|---|---|
| Peptide Name | Ipamorelin |
| Peptide Sequence | Aib-His-D-2Nal-D-Phe-Lys |
| Molecular Formula | C38H49N9O5 |
| Molecular Weight | 711.9 g/mol |
| CAS Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Synonyms | 170851-70-4, Ipamorelin [INN], NNC-26-0161, UNII-Y9M3S784Z6 |
Dosage-- This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Additional Taxes may apply for shipping to GCC
100% Authentic
Made in USA
Authorised distributor
1 - 5 days delivery
Click to read - How we deliver to India
Disclaimer
Product Information Sheet
: Not a diet substitute. Seek Medical guidance if unsure before use.
CJC-1295 & Ipamorelin Blend - Growth Hormone Secretagogue Research Complex (10 mg, No DAC)
This peptide blend combines CJC-1295 (No DAC) and Ipamorelin, two complementary growth hormone secretagogues that act on distinct receptor pathways to amplify GH release.
Mechanistic Claims
- CJC-1295 (No DAC, 5 mg)
- Synthetic GHRH analog retaining 29 amino acids of native GHRH with four substitutions for stability and receptor affinity.
- Stimulates pituitary GHRH receptors to increase pulsatile GH secretion.
- Elevates circulating IGF-1 levels, supporting anabolic and regenerative pathways.
- Mimics natural GH release patterns without prolonged receptor binding.
- Ipamorelin (5 mg)
-
- Synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).
- Selective ghrelin receptor agonist that triggers GH release from the pituitary.
- High potency with minimal off-target hormonal effects (does not significantly affect cortisol, prolactin, or ACTH).
- Provides a clean GH stimulation profile compared to other GHS compounds.
Synergistic Potential
- Dual receptor targeting (GHRH + ghrelin) amplifies GH release.
- Promotes IGF-1 elevation while maintaining physiological GH pulsatility.
- Offers a balanced approach to studying growth hormone dynamics without excessive endocrine disruption.
Research Applications
- Growth hormone secretion and regulation studies
- IGF-1 mediated anabolic and regenerative pathways
- Comparative analysis of GHRH vs. ghrelin receptor agonism
- Endocrine signaling and pituitary function models
CJC 1295 Ipamorelin Research
CJC-1295 and ipamorelin have both been researched for their potential to stimulate growth hormone production.
Ipamorelin is a potent and selective GH secretagogue with unique properties that differentiate it from other GH-releasing peptides. Its ability to selectively stimulate GH release without affecting other hormones, along with its potential applications in body composition, make it a promising candidate for further clinical development.
Growth Hormone Release
In GHRH knockout mice, CJC-1295 administration normalized body weight and length, demonstrating its potential in treating growth deficiencies. Daily administration was more effective than less frequent dosing.1
In healthy subjects, CJC-1295 led to dose-dependent increases in GH and IGF-I levels, with effects lasting up to 28 days. In the study, CJC-1295 was well-tolerated with no serious adverse reactions reported, suggesting its potential utility as a therapeutic agent.2
Ipamorelin mimics the action of ghrelin by binding to the ghrelin receptor (GHSR) in the brain, which leads to the selective stimulation of GH release from the pituitary gland. This mechanism is similar to that of GHRH, but ipamorelin does not significantly affect the release of other hormones such as ACTH or cortisol.3
In animal studies, ipamorelin has been shown to increase longitudinal bone growth and body weight gain in a dose-dependent manner. It enhances GH release without affecting other growth factors like IGF-I, suggesting a direct effect on growth processes.4
In vivo, ipamorelin shows dose-proportional pharmacokinetics with a short half-life and effectively stimulated GH release across various doses.5
References
- Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. American journal of physiology. Endocrinology and metabolism, 291 6, E1290-4 . https://doi.org/10.1152/AJPENDO.00201.2006.
- Teichman, S., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 91 3, 799-805 . https://doi.org/10.1210/JC.2005-1536.
- Raun, K., Hansen, B., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology, 139 5, 552-61 . https://doi.org/10.1530/EJE.0.1390552.
- Johansen, P., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 9 2, 106-13 . https://doi.org/10.1054/GHIR.1999.9998.
- Gobburu, J., Agersø, H., Jusko, W., & Ynddal, L. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research, 16, 1412-1416. https://doi.org/10.1023/A:1018955126402.
Peptide Information
|
Property |
Value |
|---|---|
|
Peptide Name |
CJC 1295 |
|
Peptide Sequence |
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys |
|
Molecular Formula |
C165H269N47O46 |
|
Molecular Weight |
3647.2 g/mol |
|
CAS Number |
446262-90-4 |
|
PubChem CID |
91971820 |
|
Synonyms |
CJC 1295, CJC-1295, 62RC32V9N7, DTXSID501027567 |
| Property | Value |
|---|---|
| Peptide Name | Ipamorelin |
| Peptide Sequence | Aib-His-D-2Nal-D-Phe-Lys |
| Molecular Formula | C38H49N9O5 |
| Molecular Weight | 711.9 g/mol |
| CAS Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Synonyms | 170851-70-4, Ipamorelin [INN], NNC-26-0161, UNII-Y9M3S784Z6 |
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
